University of California San Francisco
Give to UCSF
UCSF researchers successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths.
Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.
Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types.
UCSF researchers found that cancers from different parts of the body are immunologically similar to one another. They described 12 classes of "immune archetypes" to classify cancer tumors, which can provide unique strategies for enhancing patients’ choice of cancer immunotherapies.
For patients with skin cancer & facial sarcoma, reconstructing the face with skin grafted from the leg may result in poor color match. A new technique pioneered by UCSF surgeons uses pigmented tissue to achieve a better match.
Helen Diller Family Cancer Research Building Experts from UCSF Health will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the world’s largest and most
The UCSF initiative aims to increase the effectiveness and availability of chimeric antigen receptor T-cell (CAR T) therapy for lymphoma patients.
A groundbreaking national study led by UCSF finds that treating anal cancer precursor lesions reduces cancer risk for people with HIV.
A new prostate cancer test developed by UCSF and UCLA detects cancer cells that have spread to lymph nodes both inside and outside the pelvis.
Glioblastoma is the most common malignant brain tumor and among the most treatment-resistant cancers. In the last 15 years, numerous attempts to develop new drugs for glioblastoma have failed.
Researchers at UCSF and UC San Diego have mapped out how hundreds of mutations involved in two types of cancer affect the activity of proteins that are the ultimate actors behind the disease.
Researchers at UCSF have gained insight into how cancer cells proliferate despite a myriad of stresses.
Taking a page from computer engineers, biologists are trying their hands at programming cells – by building DNA circuits to guide their protein-making machinery and behavior.
T cells – immune cells that patrol our bodies in search of trouble – have become a central focus for UC San Francisco scientists working on living cell therapies, an approach that views cells
Sophie Dumont, winner of the 2021 Byers Award for Basic Science, focuses on finding out how, as well whether therapeutic targets exist to ensure equal – and healthy – division of chromosomes.
What kills most people who die from cancer is not the initial tumor. It’s the intolerable disease burden on the body that arises when tumor cells continually expand their numbers after spreading to different organs.
UCSF researchers have figured out precisely what receptor tyrosine kinases are, how they form and their role in cancer.
Loneliness and social isolation have been significant problems for the general population during the COVID-19 pandemic, but for cancer patients these issues were particularly acute, likely due to isolation and social distancing, according to a new UCSF study.
Researchers at UCSF have demonstrated how to engineer smart immune cells that are effective against solid tumors, opening the door to treating a variety of cancers that have long been untouchable with immunotherapies.
A new study suggests that the dangers posed by wildfire smoke may also extend to the largest organ in the human body, and our first line of defense against outside threat: the skin.
The study is the first comprehensive review of fatalities linked to the deadly chemical in the United States and identified more deaths than previously reported.
Cancer starts with mutations in a cell’s DNA, but new UCSF research shows that the endurance of a tumor relies on its ability to rapidly evolve and adapt to challenges brought about by the environment in which it grows.
UCSF researchers found that mice in which activity of a protein called eIF4E is diminished, either genetically or pharmaceutically, gain only half the weight of other mice, even if all the mice eat a high-fat diet.
Tissue biologist Sarah Knox has long been fascinated with saliva. Just when she begins to doubt whether her singular passion will lead to real-world impact, an old family friend reaches out to her with a problem only she may be able to solve.
Many cancer patients might respond better to treatments with the help of a new prognostic indicator based on a distinctive pattern of gene activity within tumor cells.
A new study finds that inherited genetic variation plays a role in who is likely to benefit from checkpoint inhibitors, which release the immune system’s brakes so it can attack cancer.
UCSF scientists have discovered a new way to control the immune system’s “natural killer” cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection.
Immunotherapies are a promising anticancer arsenal and work by mobilizing the immune system to recognize and destroy cancer cells. Currently, however, only a third of patients respond to
Finding medicines that can kill cancer cells while leaving normal tissue unscathed is a Holy Grail of oncology research.